Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI), Phase II Trial.
about
Platelet glycoprotein IIb/IIIa blockers during percutaneous coronary intervention and as the initial medical treatment of non-ST segment elevation acute coronary syndromesPlatelet glycoprotein IIb/IIIa blockers during percutaneous coronary intervention and as the initial medical treatment of non-ST segment elevation acute coronary syndromesPlatelet glycoprotein IIb/IIIa blockers during percutaneous coronary intervention and as the initial medical treatment of non-ST segment elevation acute coronary syndromesPercutaneous Coronary Intervention after Fibrinolysis for ST-Segment Elevation Myocardial Infarction Patients: An Updated Systematic Review and Meta-AnalysisTenecteplase: a review of its pharmacology and therapeutic efficacy in patients with acute myocardial infarctionPlatelet glycoprotein IIb/IIIa blockers for percutaneous coronary revascularization, and unstable angina and non-ST-segment elevation myocardial infarctionSimilar success rates with bivalirudin and unfractionated heparin in bare-metal stent implantationIncremental effect of clopidogrel on important outcomes in patients with cardiovascular disease: a meta-analysis of randomized trialsShort term versus long term dual antiplatelet therapy after implantation of drug eluting stent in patients with or without diabetes: systematic review and meta-analysis of individual participant data from randomised trials.Developments in endovascular therapy for acute ischemic stroke.Predictors of bleeding complications and thrombocytopenia with the use of abciximab during percutaneous coronary intervention.Occurrence, predictors, and outcomes of post-percutaneous coronary intervention thrombocytopenia in an unselected population.Validation of an automated safety surveillance system with prospective, randomized trial dataRoutine early versus deferred provisional tirofiban treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention.The Thrombolysis in Myocardial Infarction (TIMI) trials: the first decade.Platelet glycoprotein IIb/IIIa receptor antagonists and their use in elderly patients.Safety and effectiveness of enoxaparin following fibrinolytic therapy: Results of the Acute Myocardial Infarction (AMI)-QUEBEC registryThrombolytic therapy for central retinal vein occlusion: results of a pilot study.Bivalirudin is superior to heparins alone with bailout GP IIb/IIIa inhibitors in patients with ST-segment elevation myocardial infarction transported emergently for primary percutaneous coronary intervention: a pre-specified analysis from the EUROMADouble-blind, placebo-controlled Phase II studies of the protease-activated receptor 1 antagonist E5555 (atopaxar) in Japanese patients with acute coronary syndrome or high-risk coronary artery disease.Cardiac tamponade complicating myocardial infarction in the era of thrombolytics and platelet IIb/IIIa: case report and literature review.Differentiating pharmacologic agents used in catheter-directed thrombolysis.Warfarin and fibrinolysis--a challenging combination: an observational cohort study.Role of prasugrel, a novel P2Y(12) receptor antagonist, in the management of acute coronary syndromes.Influence of Access, Anticoagulant, and Bleeding Definition on Outcomes of Primary Percutaneous Coronary Intervention: Early Experience of an US Academic CenterA faster-acting and more potent form of tissue plasminogen activator.Glycoprotein IIb/IIIa receptor antagonists and risk of bleeding: a single-center experience in 1020 patients.Long-term ischaemic and bleeding outcomes after primary percutaneous coronary intervention for ST-elevation myocardial infarction in the elderlyArterial access-site complications after use of a vascular closure device related to puncture height.Trans-radial versus trans-femoral intervention for the treatment of coronary bifurcations: results from Coronary Bifurcation Stenting Registry.Incidence, Time Trends, and Predictors of Intracranial Hemorrhage During Long-Term Follow-up After Acute Myocardial InfarctionTransfer for urgent percutaneous coronary intervention early after thrombolysis for ST-elevation myocardial infarction: the TRANSFER-AMI pilot feasibility study.Fibrinolytic therapy versus primary percutaneous coronary interventions for ST-segment elevation myocardial infarction in Kentucky: time to establish systems of care?P2Y12 inhibitors in cardiovascular disease: focus on prasugrel.Usefulness of serum unbound free fatty acid levels to predict death early in patients with ST-segment elevation myocardial infarction (from the Thrombolysis In Myocardial Infarction [TIMI] II trial).Effects of omeprazole or pantoprazole on platelet function in non-ST-segment elevation acute coronary syndrome patients receiving clopidogrel.Impact of bivalirudin on mortality and bleeding complications in acute coronary syndrome patients undergoing invasive revascularization : A real world experience.Current anticoagulant safety.High-Risk Non-ST Elevation Acute Coronary Syndrome Outcomes in Patients Treated with Unfractionated Heparin Monitored Using Anti-Xa Concentrations Versus Activated Partial Thromboplastin Time.Enzymes approved for human therapy: indications, mechanisms and adverse effects.
P2860
Q24202522-0DCFE8F0-450D-4467-BF71-7F5BD26FCB3BQ24202999-80F87678-6B5D-4DF2-8234-EC245A2EA557Q24235385-6881F48F-28A4-4513-BF59-B69B4502D052Q26777456-CBFCA8EA-301F-44AC-BA1F-B4AF73C71037Q28166811-F87C1DA4-2B53-4E86-8F9B-A9D138828CCEQ28191096-14642980-5DAA-40D2-B2D9-97E5AA411CA7Q28210912-5494DEB1-67F9-4E28-BC40-A8F9EAC77357Q28219404-964AC735-2A2D-4C8C-9730-1BC086FD077CQ30241829-F23B2BF7-4AF0-45CE-B789-B6B4C34AF144Q30699588-41D856E9-BF65-47EF-B648-20162240BBE2Q33365571-C80F5673-DB85-4F73-BF93-A2DBF4AA1A80Q33383454-05525BC3-6E36-41D3-914C-A831937D4B63Q33385061-6186EEEB-943A-40AB-8E51-22E88BF14C0FQ33406801-E525383A-CB7E-4844-A22B-564251AD8678Q33568780-724AFD41-D3F3-48CB-A311-D05706752D25Q33914229-FB5CE158-DE5C-44D6-A8D5-672CBF7131C6Q34196711-94BD7F98-A77B-43ED-BC10-C5D4FBCC97BBQ34211442-5CAF337F-5A78-4AF8-A850-45C739484398Q34217697-6CE02F62-E969-49FA-AC3D-2D968FC9AB4DQ34255442-44D0BD5F-E619-4F44-9CB9-30CC0BF7CCD2Q34255828-258735DC-1F6E-4751-83DE-244FB7BFA5A2Q34563249-C5CACF23-4C2F-426F-A475-4DED30D0C1A3Q34825910-3F0BFAB9-AA4E-43C3-8C38-17A5FC62D2D4Q34995712-FA1CC462-EA39-486B-89C8-CC2630E64E8BQ35141545-FD867D8E-F2B0-4906-92EC-7795F2C8130DQ35190236-05C245D4-7122-486C-BA45-196B08F8C2C6Q35924051-ABF4F83C-E0D9-4364-9D17-F14D9FFBB686Q36087392-E02390A8-4C39-49B8-9AFA-48ABE6738113Q36283455-FABF3AF2-BCFD-4380-83E0-A3C350D30496Q36675545-ED2752C0-C2F1-41F4-8C52-DE4E209CBABCQ36836368-4A8A3957-AAB2-413A-AAF5-B52DD6261828Q36940785-C9E9C74F-6886-46A1-8EA9-7DAC7C21D078Q37104272-54A2F482-186C-4735-A675-97DA7B4298B0Q37339517-B599274C-4E22-47C7-A7A6-602C2CF34536Q37483264-CE732A1E-F845-482D-AC5D-B6004AD36120Q37508880-A6950894-55BD-4B21-870A-38D9DFD5873AQ37510674-F2611C96-ED0C-4D35-BE44-F7C450AC1885Q37990564-8B114EAE-7ACC-431D-9CDD-C452C8A74F74Q38178237-AF82314E-A31E-4790-9432-4F6424727FE4Q38342838-FE6122F7-4DDD-4B87-BE51-B16AC5943D68
P2860
Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI), Phase II Trial.
description
1991 nî lūn-bûn
@nan
1991 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
1991 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
1991年の論文
@ja
1991年論文
@yue
1991年論文
@zh-hant
1991年論文
@zh-hk
1991年論文
@zh-mo
1991年論文
@zh-tw
1991年论文
@wuu
name
Hemorrhagic events during ther ...... rction (TIMI), Phase II Trial.
@ast
Hemorrhagic events during ther ...... rction (TIMI), Phase II Trial.
@en
type
label
Hemorrhagic events during ther ...... rction (TIMI), Phase II Trial.
@ast
Hemorrhagic events during ther ...... rction (TIMI), Phase II Trial.
@en
prefLabel
Hemorrhagic events during ther ...... rction (TIMI), Phase II Trial.
@ast
Hemorrhagic events during ther ...... rction (TIMI), Phase II Trial.
@en
P2093
P921
P1476
Hemorrhagic events during ther ...... rction (TIMI), Phase II Trial.
@en
P2093
Frederick M
Lambrew CT
P304
P356
10.7326/0003-4819-115-4-256
P407
P577
1991-08-01T00:00:00Z